Clinical trials
Diffuse Cutaneous Systemic Sclerosis clinical trials
Below are recruiting diffuse cutaneous systemic sclerosis clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT07473154RecruitingPhase 1/Phase 2
Calming an overactive immune system with special cells
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
DüsseldorfAges 18 years+ - NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Birmingham, AlabamaAges 18 years+ - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Los Angeles, CaliforniaAges 18–70 - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT07287670RecruitingPhase 2
Testing MTX-474 for diffuse scleroderma
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
Phoenix, ArizonaAges 18 years+ - NCT03844061RecruitingPhase 2
Belimumab plus rituximab for early diffuse scleroderma skin disease
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
New York, New YorkAges 18–80 - NCT05149768RecruitingPhase 2
Study extension of Adcetris for worsening early skin sclerosis
This trial is a follow-up study that keeps studying Adcetris (brentuximab vedotin) in people with worsening diffuse cutaneous systemic sclerosis (dcSSc) who were in an earlier Adcetris study. It aims to see if the treatment continues to help your skin symptoms over time and stays safe.
London, OntarioAges 18 years+ - NCT06058091RecruitingPhase 1/Phase 2
Cell injection therapy for systemic sclerosis
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
Nanjing, JiangsuAges 18–65 - NCT06375005RecruitingPhase 2
Telitacicept for early diffuse scleroderma
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Yangzhou, JiangsuAges 18–70 - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Mesa, ArizonaAges 18–70 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06936215RecruitingPhase 3
Baricitinib vs methotrexate for skin tightening in scleroderma
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
DhakaAges 18 years+ - NCT07047690RecruitingPhase 2
Nemolizumab for adults with scleroderma
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Ann Arbor, MichiganAges 18 years+ - NCT07360808Recruiting
Fat Cell Therapy for Hand Problems in Scleroderma
This study tests whether a person's own fat cells (processed into regenerative cells) can be injected into the hands to improve hand function and reduce skin thickening in systemic sclerosis (scleroderma). It’s designed for people whose hand problems are significant but not too severe.
Guangzhou, GuangdongAges 18–70 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT04917705Recruiting
Blood and tissue tests to find markers in muscle and skin disease
This study looks for blood and tissue “biomarkers” (measurable clues in samples) to help diagnose and predict outcomes in inflammatory muscle diseases and systemic sclerosis (a skin/organ condition). If you’re being evaluated for myopathy or early scleroderma, it may help doctors sort out the cause and follow your health more closely.
Strasbourg, Bas-RhinAges 18 years+ - NCT06954597RecruitingPhase 2
Testing a new cream for scleroderma finger ulcers
This study tests a new cream (TOP-N53) for digital ulcers caused by scleroderma. The cream is applied directly to the sore, and the goal is to see if it is safe and helps the ulcer heal.
BordeauxAges 18 years+ - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Diffuse Cutaneous Systemic Sclerosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for diffuse cutaneous systemic sclerosis?
- Yes. Clin2 currently lists 35 recruiting diffuse cutaneous systemic sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse cutaneous systemic sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse cutaneous systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.